Skip to content

Telix Pharmaceuticals

Telix is harnessing the power of targeted radiation to see and treat cancer.

Last updated September 1, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Telix Pharmaceuticals is an Australian public company focused on developing targeted radiopharmaceuticals for cancer diagnosis and therapy. Its theranostic approach pairs imaging agents with therapeutics to improve patient outcomes. The company has commercial products Illuccix and Gozellix for prostate cancer imaging and is advancing a pipeline across urologic oncology, neurologic oncology, and other solid tumors.

History

Telix Pharmaceuticals is an Australian public company. It is harnessing the power of targeted radiation to see and treat cancer, with a theranostic approach that pairs radiopharmaceutical imaging agents and therapeutics. The company has commercial products Illuccix and Gozellix for prostate cancer imaging, and is advancing a pipeline across urologic oncology, neurologic oncology, and other solid tumors.

Products and positioning

  • Illuccix®

    Approved in United States, Canada, Australia, United Kingdom, Brazil and countries in the European Union for prostate cancer imaging.

  • Gozellix®

    Approved by the United States Food and Drug Administration (FDA) for prostate cancer imaging.

Sources8 sources

Cite this profile: Cite the canonical profile. /brand-wiki/telix-pharmaceuticals-limited · Editorial policy · How profiles are compiled